The research highlights the evolution of treatment for early breast cancer, emphasizing the effectiveness of systemic adjuvant therapy in reducing mortality rates and improving prognosis over the past 30 years. Despite advancements, concerns about distant recurrence remain, prompting the need for further research to enhance treatment options and patient outcomes.

This study analyzes real-world clinical outcomes of patients with early relapsed triple-negative breast cancer (mTNBC) using data from the ESME national cohort. It finds that patients with early relapse have significantly poorer overall survival and progression-free survival compared to those with late relapse, highlighting the urgent need for improved treatment strategies for this aggressive cancer.

Most women living in low- and middle-income countries (LMICs) present with advanced-stage breast cancer. Limitations of poor serviceable health systems, restricted access to treatment facilities, and lack of breast cancer screening programmes all likely contribute to the late presentation of women with breast cancer living in these countries. Women are diagnosed with advanced disease and frequently do not complete their care due to a number of factors, including financial reasons as health expenditure is largely out of pocket resulting in financial toxicity; health system failures, such as missing services or health worker lack of awareness on common signs and symptoms of cancer; and sociocultural barriers, such as stigma and use of alternative therapies. Clinical breast examination (CBE) is an inexpensive early detection technique for breast cancer in women with palpable breast masses.